drugset / Trial / NCT00334672

Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis

NCT00334672

Phase 3 Unknown 288 enrolled Children's Cancer and Leukaemia Group
Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of hemophagocytic lymphohistiocytosis cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more hemophagocytic lymphohistiocytosis cells. A donor stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Cyclosporine and methotrexate may stop this from happening. PURPOSE: This phase III trial is studying how well combination chemotherapy followed by a donor stem cell transplant works in treating patients with hemophagocytic lymphohistiocytosis.

Timeline

Start
2006-03
Primary completion
2010-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide Intravenous
Subject Dexamethasone Small molecule Intravenous
Subject Etoposide Small molecule Intravenous
Background ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic Intravenous
Background Busulfan Small molecule Oral
Background Cyclophosphamide Other / unclassified Intravenous
Background Hydrocortisone Other / unclassified Intrathecal
Background Methotrexate Small molecule Intrathecal
Background Mycophenolate Mofetil Small molecule Oral

Indications

No indication recorded.